News and Announcements
Cre8tek (ASX: CR8) Completes $3.5m Placement, Signs 3rd Trial Agreement with a US-Based Insurance Company & Wins Contract with Metlife Asia
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cre8tek Limited (ASX:CR8) owner of high-tech, Artificial Intelligence company, Flamingo Customer Experience Inc. has recently provided an update on the activities for the three months ended 30 June 2017.
KEY TAKEAWAYS:
- Signed a Trial Agreement contract with a third US based insurance company
- North American and Australian customer paid trials progressing into implementation and integration, with two in User Acceptance Testing (UAT)
- Flamingo continues to execute its North American strategy with a growing pipeline
- AsiaPacfi8c expansion strategy commenced with the winning of Judge’s Selection for Asia based contract with Metlife Asia. Flamingo was one of three winners of a contract with MetLife Asia, from 8 Finalists and 140 entrants – globally
- Successful completion of $3.5m placement to sophisticated and institutional investors
- Receipt of the R&D Tax Incentive of $723k
- Significant progress undertaken on the development of new product, Virtual Inquiry Assistant
- Submission of additional patent applications for the JourneyAssist and ROSIE machine learning technology in 14 jurisdictions
- Strong interest in the US, Australia and Asian markets continues to strengthen the sales pipeline
The Company’s key focus over the remainder of CY17 is the execution of current paid client implementations across Australia and the North American markets. This includes establishing operational capabilities across Australia and the US to support live clients with 24×7 support infrastructure. In addition, the Company will continue to progress efforts and resources into maintaining a high level of security capability in the Flamingo platform and a Culture of Security across the business.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
